What Is Mounjaro?
Published May 2, 2026 - 7 minute read
Mounjaro is one of the names that made the GLP-1 conversation harder to describe in one sentence. It is a type 2 diabetes drug, a tirzepatide brand, a dual incretin receptor agonist, and a product people often compare with Ozempic and Zepbound even though those names do not all mean the same thing.
Key Takeaways
- Mounjaro is the brand name for tirzepatide injection.
- Its current U.S. label is for type 2 diabetes glycemic control in adults and children 10 years and older.
- Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is why Mounjaro is discussed with GLP-1 drugs.
- Ozempic contains semaglutide; Mounjaro contains tirzepatide.
- Zepbound also contains tirzepatide, but it has different U.S. brand labeling.
1. The Short Answer
Mounjaro is an injectable prescription medicine whose active ingredient is tirzepatide. The current DailyMed label describes Mounjaro as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated with diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
The Mounjaro official site uses plainer language: Mounjaro is used along with diet and exercise to improve blood sugar in adults and children 10 years and older with type 2 diabetes. The same official page also states that Mounjaro is not a weight loss drug.
That last sentence is where many searches go sideways. Mounjaro is widely discussed in weight-loss conversations because tirzepatide can affect appetite and body weight, and because the same active ingredient is used under the Zepbound brand. But in the United States, the Mounjaro brand label is a type 2 diabetes label.
2. What Is Tirzepatide?
Tirzepatide is the active ingredient in Mounjaro. In Mounjaro’s prescribing information, tirzepatide is described as a GIP receptor and GLP-1 receptor agonist; the useful nontechnical point is that one molecule is designed to activate two incretin-related receptor pathways.
Incretins are hormones involved in meal-related metabolic signaling. GLP-1 is the better-known pathway because drugs such as semaglutide, liraglutide, dulaglutide, and exenatide made “GLP-1” familiar. GIP is another incretin hormone pathway. Tirzepatide is often called a dual agonist because it activates both GIP and GLP-1 receptors.
NCBI Bookshelf’s GLP-1 receptor agonist review places tirzepatide near the GLP-1 category while spelling out the distinction: tirzepatide is a GIP analog that activates both GLP-1 and GIP receptors. That is the cleanest way to talk about it without flattening the science into “just another GLP-1.”
3. Why Is Mounjaro Discussed With GLP-1s?
Mounjaro is discussed with GLP-1 medications because tirzepatide includes GLP-1 receptor activity, appears in the same diabetes and weight-management conversations, and is often compared with semaglutide products. The shorthand is understandable. It is also incomplete.
In everyday language, “GLP-1 drugs” often means a broad public category: Ozempic, Wegovy, Mounjaro, Zepbound, and sometimes older incretin-based medicines. That public category is useful for headlines but imprecise for labels. Ozempic and Wegovy contain semaglutide. Mounjaro and Zepbound contain tirzepatide. Some are diabetes brands, some are weight-management brands, and some have additional labeled uses.
The better wording depends on the point being made:
| If you mean… | More precise wording |
|---|---|
| The Mounjaro brand | Mounjaro |
| The active ingredient | Tirzepatide |
| The receptor profile | Dual GIP and GLP-1 receptor agonist |
| The broad public category | GLP-1 and incretin-based medications |
| The U.S. diabetes label | Mounjaro for type 2 diabetes glycemic control |
Precision matters because brand names do not carry the whole label.
4. Mounjaro vs Ozempic
Mounjaro and Ozempic are both discussed in type 2 diabetes and GLP-1 conversations, but they are not the same drug. The central difference is the active ingredient: Mounjaro contains tirzepatide, while Ozempic contains semaglutide.
The Ozempic DailyMed label describes Ozempic as a GLP-1 receptor agonist. The Mounjaro label describes tirzepatide as a GIP receptor and GLP-1 receptor agonist. That makes the receptor profile different at a high level.
The labels differ too. Ozempic’s current U.S. injection label includes glycemic control in adults with type 2 diabetes, plus cardiovascular and chronic kidney disease risk-reduction indications in defined adult type 2 diabetes populations. Mounjaro’s current label is centered on improving glycemic control in type 2 diabetes in adults and pediatric patients 10 years and older.
That comparison is a naming and label comparison, not a recommendation. It keeps the comparison at the naming-and-label level rather than turning it into product choice, switching, or use guidance.
5. Mounjaro vs Zepbound
Mounjaro and Zepbound are easier to confuse because both contain tirzepatide in the United States. The difference is the brand label and the labeled use, not the active ingredient name.
The FDA’s 2023 Zepbound approval announcement states that tirzepatide, Zepbound’s active ingredient, was already approved under the Mounjaro trade name for type 2 diabetes. The same announcement describes Zepbound as a chronic weight-management approval for adults with obesity or adults with overweight and at least one weight-related condition, used with reduced calorie diet and increased physical activity.
The current Zepbound DailyMed label also includes treatment of moderate to severe obstructive sleep apnea in adults with obesity. FDA announced that OSA approval on December 20, 2024.
So the high-level map is:
| Name | Active ingredient | High-level U.S. label context |
|---|---|---|
| Mounjaro | Tirzepatide | Type 2 diabetes glycemic control |
| Zepbound | Tirzepatide | Chronic weight management and moderate to severe OSA in adults with obesity |
| Ozempic | Semaglutide | Type 2 diabetes, with additional defined cardiovascular and kidney-related indications |
Same active ingredient does not mean same brand label, same coverage, same patient instructions, or automatic substitution. Those are regulated and clinical questions outside this explainer.
6. Why Brand and Generic Names Get Confusing
The confusion starts because people usually learn these drugs through brand names. “Ozempic” becomes a cultural shortcut. “Mounjaro” becomes the diabetes brand people associate with tirzepatide. “Zepbound” becomes the weight-management and OSA brand. “Tirzepatide” is the active ingredient underneath two of those names.
Then the class names add another layer. GLP-1 can mean a natural hormone, a receptor, a receptor-agonist medication class, or a casual shorthand for newer metabolic drugs. Tirzepatide fits the public shorthand because it activates the GLP-1 receptor, but it is more precise to call it a dual GIP and GLP-1 receptor agonist.
One clean way to keep the names straight is to ask three separate questions:
- What is the brand name?
- What is the active ingredient?
- What does the current label say the brand is for?
Those questions separate language from medical decisions. They also avoid turning a brand comparison into a treatment recommendation.
7. Sources
References used for this article
8. Mounjaro FAQ
What is Mounjaro in simple terms?
Mounjaro is the brand name for tirzepatide injection. The current U.S. label describes it as a GIP and GLP-1 receptor agonist used with diet and exercise to improve blood glucose in adults and children 10 years and older with type 2 diabetes mellitus.
Is Mounjaro a GLP-1?
Mounjaro is often discussed with GLP-1 medications because tirzepatide activates the GLP-1 receptor. The more precise description is dual GIP and GLP-1 receptor agonist, because tirzepatide also activates the GIP receptor.
How is Mounjaro different from Ozempic?
Mounjaro contains tirzepatide and is described as a dual GIP and GLP-1 receptor agonist. Ozempic contains semaglutide and is described as a GLP-1 receptor agonist. They are different active ingredients with different labels, not interchangeable names.
Is Mounjaro the same as Zepbound?
Mounjaro and Zepbound both contain tirzepatide in the United States, but they are different brand labels. Mounjaro is labeled for type 2 diabetes glycemic control. Zepbound is labeled for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity.